Biotech developing next-generation antibody-drug conjugates for solid tumours
| Date | Round | Amount |
|---|---|---|
| Oct 2022 | Series A Mablink Bioscience, a Lyon biotech building stealth antibody-drug conjugates for cancer, raised €31M Series A co-led by Sofinnova Partners and Merieux Equity Partners to advance its lead candidate into the clinic. | $31M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.